What will be the cost of Keir Starmer’s new medicines deal with Donald Trump? British lives | Aditya Chakrabortty

The article discusses a new medicines deal between the governments of Keir Starmer and Donald Trump, which is being touted as a "world-beating deal" by the UK government. The deal will see more than £3 billion that could have been used for UK patients being diverted to big pharma for its branded products, siphoning off money that could have gone towards patient care. The article draws a parallel to Arthur Scargill, the former miners' leader, who would read the Financial Times before the Morning Star, in order to "get the facts" before imbibing views. It suggests that the public should take a similarly impartial approach in parsing this new agreement, which has significant financial and political implications, despite the government's claims that it will benefit "tens of thousands of NHS patients." The article highlights the concern that this deal will prioritize profits for pharmaceutical companies over the needs of UK patients, and questions whether the cost of Keir Starmer's new medicines deal with Donald Trump will be British lives.